The BioPharm Brief: Rare Disease Trials, mRNA Innovation, and Funding

Oct 08, 08:45 PM
Headliner
Share
Subscribe

Welcome to The BioPharm Brief, your daily snapshot of the latest developments shaping biopharmaceutical research, clinical progress, and drug development. Today’s update examines the path forward for a rare disease gene therapy, new funding for cell-based messenger RNA manufacturing, and how regulatory incentives can help finance future treatments for rare diseases.

Share
Subscribe
Next
The BioPharm Brief: Advancing ADCs, Biosimilars and CAR-T Therapies
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Cancer, Personalized
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief